[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658453":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":21,"armGroups":22,"interventions":28,"overallOfficials":38,"centralContacts":43,"locations":52,"responsibleParty":73,"collaborators":75,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":17,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":94,"studyType":95,"phases":17,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":55,"whyStopped":17,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13],{"measure":10,"description":11,"timeFrame":12},"PFS","progression-free survival","from the first date of administration to the date of tumor progression (up to 36 months)",{"measure":14,"description":15,"timeFrame":16},"OS","overall survival","from the first date of administration to the date of death (up to 36 months)",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","patients who have radiologically suspected PCNSL",[23],{"label":24,"type":17,"description":17,"interventionNames":25},"Radiologically suspected PCNSL",[26,27],"Drug: HD-MTX-based chemotherapy","Drug: BTK inhibitor",[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":17},"DRUG","HD-MTX-based chemotherapy","High-dose methotrexate-based chemotherapy",[24],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":17},"BTK inhibitor","Bruton's Tyrosine Kinase inhibitor",[24],[39],{"name":40,"affiliation":41,"role":42},"Xiaohui Ren","Department of Neurosurgery, Beijing Tiantan Hospital","PRINCIPAL_INVESTIGATOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":17,"email":48},"Xiaohui Ren, MD","CONTACT","+86-010-59975567","xiaohuiren@mail.ccmu.edu.cn\u002Fxiaohuiren@aliyun.com",{"name":50,"role":46,"phone":47,"phoneExt":17,"email":51},"Haoyi Li, MD","lee_627269051@163.com",[53],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Deparment of neurosurgery, Beijing tiantan hospital","RECRUITING","Beijing","Beijing Municipality","100070","China","CN",{"type":62,"coordinates":63},"Point",[64,65],116.39723,39.9075,{"lat":65,"lon":64},[68,69,70,71],{"name":45,"role":46,"phone":47,"phoneExt":17,"email":48},{"name":50,"role":46,"phone":47,"phoneExt":17,"email":51},{"name":45,"role":42,"phone":17,"phoneExt":17,"email":17},{"name":72,"role":42,"phone":17,"phoneExt":17,"email":17},"Hanxiao Zhou, MD",{"type":74,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"SPONSOR_INVESTIGATOR",[76,78],{"name":77,"class":6},"Beijing Neurosurgical Institute",{"name":79,"class":80},"Guangzhou Burning Rock Medical Examination Institute Co., Ltd.","INDUSTRY","100658453","rapid-diagnosis-and-treatment-response-monitoring-of-primary-cns-lymphoma-using-csf-ctdna-liquid-biopsy-100658453",false,"NCT07851363","Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy","Rapid Diagnosis and Treatment Response Monitoring of Primary Central Nervous System Lymphoma Using Cerebrospinal Fluid Circulating Tumor DNA Liquid Biopsy","Inclusion Criteria:\n\n* Patients with pathologically confirmed primary central nervous system lymphoma;\n* Lesions confined to the central nervous system (cerebral parenchyma, meninges, spinal cord or intraocular), with no evidence of systemic lymphoma;\n* Aged ≥ 18 years and ≤ 75 years, no restriction on gender;\n* Expected survival of more than 3 months;\n* The subjects voluntarily join this study, understand the trial procedures and contents, sign the informed consent form, have good compliance and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Other types of central nervous system tumors;\n* Without pathological confirmation basis;\n* Patients complicated with other malignant tumors;\n* Other conditions that are considered by the investigators to be unsuitable for participating in this trial.","ALL","18 Years","75 Years",{"count":92,"type":93},300,"ESTIMATED","3 Years","OBSERVATIONAL","The incidence of primary central nervous system lymphoma (PCNSL) has increased steadily, and the disease often progresses rapidly, with many patients presenting in critical condition. Timely biopsy and rapid pathological diagnosis are therefore essential for emergency management. However, biopsy is invasive and limited by bleeding risk, surgical contraindications, restricted tissue availability, and the effects of corticosteroid exposure or sampling location on pathological assessment. Moreover, delays inherent in imaging-based evaluation hinder the detection of very early relapse and may adversely affect patient outcomes.\n\nThe investigators have focused on precision diagnosis and treatment of PCNSL, established an emergency-to-pathology rapid-response system and provided preliminary evidence from a small cohort that cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) has distinctive value for diagnosis and treatment-response assessment. A key biomarker-based panel achieved 100% specificity and 85% sensitivity.\n\nThis project aims to establish a large, multicenter, disease-specific PCNSL database and characterize ctDNA alterations across more than 100 genes using ultra-deep sequencing. This project will integrate longitudinal CSF ctDNA profiles collected across disease stages with matched tissue-sequencing data. This approach will delineate the dynamic evolution of ctDNA molecular features and their spatiotemporal relationship with intratumoral heterogeneity. By developing multimodal AI models, the project aims to enable rapid early diagnosis, treatment-response prediction, and longitudinal disease monitoring, while elucidating mechanisms of therapeutic resistance and ultimately improving patient outcomes.",[98],"Primary Central Nervous System Lymphoma",[100,101,102,103],"primary central nervous system lymphoma","cerebrospinal fluid circulating tumor DNA","AI","treatment monitoring","2026-09-25",{"date":106,"type":107},"2026-10-01","ACTUAL",{"date":109,"type":107},"2026-01-01",{"date":111,"type":93},"2029-12-31",{"name":40,"class":6},1]